Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
137 Leser
Artikel bewerten:
(0)

Quantel Medical Announces Two New Ultrasound Probes at ASCRS

SAN FRANCISCO, April 20, 2013 /PRNewswire/ --Quantel Medical today announced the introduction of two new diagnostic ultrasound probes to their flagship ultrasound platform, Aviso', at the American Society of Cataract and Refractive Surgery annual meeting. The new probes offer improved diagnosis capability for posterior and anterior segment ophthalmic conditions.

The new 50 MHz high-frequency ultrasound biomicroscope (UBM) probe now includes a state-of-the art magnetic transducer. The scanning motion in the ultrasound is controlled through magnetic fields instead of mechanical movements as in previous versions. This new technology offers a faster scanning process, which has increased the image resolution by one-third. Additional benefits include a lighter-weight design and less vibration when performing an ultrasound, reducing fatigue to the user. The reliability and durability of the probe is also improved by eliminating mechanical components.

The new 10 MHz B-scan probe offers similar benefits for posterior pole diagnosis. This B-scan probe provides superior image quality for viewing and assessment of the detailed structures in the vitreous and the orbital wall. Increased image acquisition rate allows for high-definition characterization of ocular structures and their movements. The dynamic gain functionality of the 10 MHz allows users to adjust settings to find the optimal tissue differentiation in the image, allowing for more visual clarity and better understanding of the condition of the eye.

"These two product introductions reflect Quantel's commitment to developing the most robust and advanced ultrasound technology available to ophthalmologists," stated Mr. Jean-Marc Gendre, CEO of Quantel Medical. "Image quality and ease of acquisition are two critical features that we strive to improve and provide to our customers."

The Aviso ultrasound platform is configurable to include the new 50 MHz and 10 MHz probes, as well as biometry and Standardized echography modules. Quantel Medical's line of posterior and anterior segment ultrasound diagnostic systems provide eye care physicians of all specialties with a critical tool for understanding pathology and obtaining accurate measurements.

About Quantel Medical
Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the treatment of ocular diseases. Quantel Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions, and a comprehensive product portfolio of diagnostic ultrasound and surgical lasers for ophthalmologists. The products are available through direct sales operations in the U.S. and France, and through independent distributors in over 80 countries.

Quantel Medical is a division of Quantel (QUA:EN), a world-wide leader in the development of solid-state lasers for scientific and industrial applications.

www.quantel-medical.com

SOURCE Quantel Medical

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.